Why ML Capital Group Inc (OTCMKTS:MLCG) Shares Are Skyrocketing
ML Capital Group Inc (OTCMKTS:MLCG) shares soared 144.44% on Wednesday to $0.00220. The company has a market cap of $2.94 million at 1.34 billion shares outstanding. Share prices have been trading in a 52-week range of $0.00 to $0.00.
ML Capital Group Inc is a company that is engaged in the business of providing consulting services to both public and private companies. It primarily focuses on early stage companies, small businesses and emerging growth companies and is producing products and providing services that support the medical marijuana industry. In particular, it produces and markets its products and services under the Superstar Products brand name, including vapor pens, mobile applications and books. The focus of the ML Capital Group Inc is to sell products and services that do not include the growing, manufacture, or distribution of medical marijuana, cannabis, or cannabis byproducts.
Just recently, the company announced that they will be working together with Puration to introduce Cannabis Tourism to the New York Times. This also follows Puration’s $1 million collaboration agreement with Colorado based Spanish Peaks
ScrumpDelicacies and ML Capital Group Inc’s letter of intent to acquire Spanish Peaks ScrumpDelicacies, which is venture-backed startup dedicated to building cannabis consumer product production capacity in Colorado.
In this week’s press release, ML Capital Group Inc announced the company plans to publish an online presentation today to provide more details on the company’s preliminary sales forecast for 2017, which includes contributions from its fresh entry into the cannabis sector with its Puration partnership.
This partnership between MLCG, PURA and Spanish Peaks is a sound strategy for every participant, and an opportunity for the shareholders of every participant to take part in the history making and money making transition from an illegal marijuana market to a legal one,” the company’s press materials indicated.
It started off by projecting that travel sales are expected to reach $2.5 trillion by 2020. To take advantage of this, ML Capital Group Inc has zeroed in on the luxury sub-segment and already operates a luxury tour service in Hawaii. It has also recognized the expanding role of mobile technology within the travel industry and launched an initiative to build a mobile brand.
It also delved into the segmentation potential of the marijuana industry, as cannabis-infused edibles and cosmetics add to potential sales revenues, on top of merchandise. It compared the luxury cannabis tour segment to winery and distillery tours in Napa Valley or Tuscany, citing Colorado’s $19 billion travel market as a strong opportunity for the company to tap into this type of market. This is already in the works and additional Cannabis Tour locations, to include destinations outside the United States, are also underway.
Looking at the daily chart of ML Capital Group Inc shares shows a strong rally so far this year, spurred by its partnership with Puration. Volume has considerably spiked, reflecting strong investor interest, which might likely sustain the bullish move to new heights. It’s also worth noting that price is gearing up to move past the previous peak around March to May last year.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
Bullish Updates for Medifirst Solutions Inc (OTCMKTS:MFST)
Medifirst Solutions Inc (OTCMKTS:MFST) shares rose 12.12% on Tuesday to $0.00370 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.02. The company has a market cap of $561,734.00 at 138.02 million shares outstanding.
Medifirst Solutions Inc is a development-stage company that is engaged in developing medical devices. Under a manufacturing agreement, the company produces its hand-held mobile laser system known as The Time Machine Program. Through its subsidiary Medical Laser Manufacturer Inc, it has entered into a Product and Know-How License Agreement with Laser Lab Corp to license the use of various properties in connection with seeking regulatory approval for and marketing, distributing and selling The Time Machine Series Lasers or TTM Series.
In addition to the license granted to Medifirst Solutions Inc, the License Agreement provides for an option to license other fields of use of the infrared laser in the TTM Series, as well as other wavelengths and colors, allowing it to develop a range of product offerings. The Time Machine Infrared Laser 810/830-nanometer operates in continuous wave mode set at a fixed frequency.
In a press release, Medifirst Solutions Inc shared that its President and Medical Director will be presenting its FDA cleared laser technology at a medical conference on January 27th in Casablanca and on February 1st in Dubai. The former will host about 100 physicians who will be specifically attending to see a presentation and demonstration of the Infrared Time Machine Laser.
The company also shared that medical distributors in both Morocco and Dubai have inquired about its time frame and capacity to produce and ship large bulk orders. Because of that, Medifirst Solutions Inc has decided to ramp up production in anticipation of bulk purchase orders. Its representatives will also be meeting with representatives of the Moroccan Ministry of Health who have the authority to purchase medical devices for all the hospitals in the country. Apart from that, Medifirst Solutions Inc has plans to set up a distribution hub in Morocco that would expedite future orders in that region.
After we complete our demonstration and presentation, we anticipate finalizing the initial sales and fulfillment process. This is just the beginning of what we hope is a long term business relationship in the region,” remarked Medifirst Solutions Inc President Bruce Schoengood.
In Dubai, company representatives will also be meeting representatives of a Saudi Arabia based medical distributor that has requested exclusive rights for four countries in the region.
We are excited to have the opportunity to meet distributors who have the buying power for bulk orders of our Laser. Medifirst will also be meeting with several Dubai based medical distributors who have requested to meet the Medifirst management regarding sales and distribution for the Time Machine Lasers,” added Schoengood.
Looking at the stock’s long-term chart, though, shows that it has yet to pull up from its dive. It’s worth noting that investor interest has been climbing as volume has been increasing since December last year and has spiked early this year. Further bullish momentum could allow the stock to climb up to the next area of interest around $0.005.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.
Here’s Who Just Picked Up Comstock Resources Inc. (NYSE:CRK) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Comstock Resources Inc. (NYSE:CRK) reported that Westcott Carl H has picked up 1,141,800 of common stock as of 2017-01-17.
The acquisition brings the aggregate amount owned by Westcott Carl H to a total of 1,141,800 representing a 8.49% stake in the company.
For those not familiar with the company, Comstock Resources, Inc. is an energy company engaged in the acquisition, exploration, development and production of oil and natural gas in the United States. The Company operates in the segment of exploration and production of oil and natural gas. The Company’s oil and gas operations are concentrated in Texas and Louisiana. Its operations are focused in two operating areas: East Texas/North Louisiana and South Texas. The Company’s properties in the East Texas/North Louisiana region include approximately 80,660 acres in the Haynesville or Bossier shale formations. The Company’s Eagleville field includes approximately 30,220 acres located in the oil window of the Eagle Ford shale in South Texas. The Company owns interests in over 1,575 producing oil and natural gas wells, and operates over 950 of these wells. The Company owns interests in over 20 wells in the Rosita field, located in Duval County, Texas.
A glance at Comstock Resources Inc. (NYSE:CRK)’s key stats reveals a current market capitalization of 136.58 million based on 13.46 million shares outstanding and a price at last close of $10.12 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-15, Martin picked up 5,500 at a purchase price of $8.95. This brings their total holding to 34,524 as of the date of the filing.
On the sell side, the most recent transaction saw Allison unload 8,000 shares at a sale price of $10.12. This brings their total holding to 393,919.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Comstock Resources Inc. (NYSE:CRK) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Biotech Is Hot And Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) Is Benefiting
Healthcare is hot right now, and there’s no hotter space from a fund perspective than oncology. Here’s a look at the Vertical Fund’s latest equity acquisition, a position taken in small cap cancer focus biotech, Oncomed.
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) reported that Vertical Fund I Lp has picked up 1,119,905 of common stock as of 2017-01-13.
The acquisition brings the aggregate amount owned by Vertical Fund I Lp to a total of 1,119,905 representing a 3.0% stake in the company.
For those not familiar with the company, OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company’s Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company’s Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.
A glance at Oncomed Pharmaceuticals Inc. (NASDAQ:OMED)’s key stats reveals a current market capitalization of 277.08 million based on 37.09 million shares outstanding and a price at last close of $8.02 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-09-30, Lasersohn picked up 9,120 at a purchase price of $16.26. This brings their total holding to 46,560 as of the date of the filing.
On the sell side, the most recent transaction saw Park unload 21,369 shares at a sale price of $8.52. This brings their total holding to 37,323.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Bulls Warming Up for New Colombia Resources Inc (OTCMKTS:NEWC) Shares
New Colombia Resources Inc (OTCMKTS:NEWC) shares were flat on Friday at $0.0280 and also unchanged in after-hours trading at $0.0280. Share prices have been trading in a 52-week range of $0.00 to $0.05. The company has a market cap of $4.32 million at 154.34 million shares outstanding.
New Columbia Resources Inc is a metallurgical coal company that is engaged in the acquisition and development of high quality metallurgical coal producers in Colombia. It is focusing on its La Tabaquera coal and rock project located in the Municipality of Guaduas, approximately 100 kilometers northwest of Bogota. The 57 hectares La Tabaquera and the 390 hectares mine La Herradura, are located to the west of the La Bermeja Ravine, crossing Rio Guaduero from north to south, with a linear extension of 2.5 kilometers north-south direction and 0.2 kilometers approximately from east-west. Its rock crushing plant has a processing capacity of over 100 cubic meters per hour of aggregates. It also has a medical cannabis business in Colombia operating as Sannabis SAS.
Earlier this month, New Columbia Resources Inc signed a $90 million purchase agreement for metallurgical coal with American Steel Industries of Philadelphia under a joint venture with a Chinese government-owned giant in the commodities and steel trading segment. American Steel Industries has been exporting steel from China for the past 12 years and is one of its largest steel exporters.
According to the company’s press release, the new contract will be filled by New Colombia’s joint venture with MSG Mining Corp. Some of the coal will be supplied by the joint venture’s Mina San Gregorio in Cucuta, Colombia while the remainder will be sourced from third-party producers. It will then be stored at New Columbia Resources Inc’s coal yard in Cucuta with a 50,000 ton capacity and industrial scale, then trucked or barged to a port on the Caribbean coast for shipment to South China. Analysts have remarked that opportunities for metallurgical coal are on a strong bullish ride from last year as demand continues to pickup and larger orders are being fulfilled.
To top it off, New Columbia Resources Inc also announced that it is developing a portfolio of medical marijuana products, and intends to submit an Orphan Drug application to the FDA in the US through a partnership with Advanced Imaging Projects LLC. Cannabis companies have been faring really well at the start of this year, following the bullish momentum sparked by the November 8 vote to legalize the use of medical or recreational marijuana in several U.S. states. This has led analysts to project that the cannabis sector could grow to $7.1 billion this year and $20 billion by 2020.
The company shared that they have reserved a spot in the USA Today’s 2017 Special Edition Colorado Rockies Preview to advertise Sannabis’ SANNAXHOL Pain Cream topical product made of cannabis sativa flower and other all natural ingredients native to Colombia. The pain cream has been tested by a licensed medical marijuana testing facility in the U.S. and shown to have minimal traces of THC, which can be imported and sold in the country.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.